Paolo Manzoni

Summary

Publications

  1. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97 pubmed publisher
    ..After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection. ..
  2. Manzoni P, Mostert M, Jacqz Aigrain E, Farina D. The use of fluconazole in neonatal intensive care units. Arch Dis Child. 2009;94:983-7 pubmed publisher
    ..This article summarises current evidence on the use of fluconazole in preterm neonates and discusses the concerns surrounding its use in nurseries. ..
  3. Manzoni P, Guardione R, Bonetti P, Priolo C, Maestri A, Mansoldo C, et al. Lutein and zeaxanthin supplementation in preterm very low-birth-weight neonates in neonatal intensive care units: a multicenter randomized controlled trial. Am J Perinatol. 2013;30:25-32 pubmed publisher
    ..No significant effect was seen on threshold ROP, NEC, or BPD. The decreasing trends of these outcomes in the treatment group need to be assessed and confirmed on larger sample-sizes. ..
  4. Manzoni P. Clinical Benefits of Lactoferrin for Infants and Children. J Pediatr. 2016;173 Suppl:S43-52 pubmed publisher
    ..These randomized controlled trials demonstrate that lactoferrin has a clinically significant impact on feeding, the microbiome, and clinical outcomes in neonates and infants. ..
  5. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo M, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012;129:116-23 pubmed publisher
    ..No effect is seen on colonization. The protective effect on IFI is likely due to limitation of ability of fungal colonies to progress toward invasion and systemic disease in colonized infants. ..
  6. Manzoni P, De Luca D, Stronati M, Jacqz Aigrain E, Ruffinazzi G, Luparia M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81-8 pubmed publisher
    ..Additional measures may include the use of lactoferrin, fluconazole, and nystatin and specific measures to prevent ventilator associated pneumonia. ..
  7. Manzoni P, García Sánchez R, Meyer M, Stolfi I, Pugni L, Messner H, et al. Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactoferrin Counteracts This Effect. J Pediatr. 2018;193:62-67.e1 pubmed publisher
    ..Exposure to inhibitors of gastric acidity is significantly associated with the occurrence of LOS in preterm VLBW infants. Concomitant administration of BLF counteracts this selective disadvantage. isrctn.org: ISRCTN53107700. ..

Detail Information

Publications7

  1. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97 pubmed publisher
    ..After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection. ..
  2. Manzoni P, Mostert M, Jacqz Aigrain E, Farina D. The use of fluconazole in neonatal intensive care units. Arch Dis Child. 2009;94:983-7 pubmed publisher
    ..This article summarises current evidence on the use of fluconazole in preterm neonates and discusses the concerns surrounding its use in nurseries. ..
  3. Manzoni P, Guardione R, Bonetti P, Priolo C, Maestri A, Mansoldo C, et al. Lutein and zeaxanthin supplementation in preterm very low-birth-weight neonates in neonatal intensive care units: a multicenter randomized controlled trial. Am J Perinatol. 2013;30:25-32 pubmed publisher
    ..No significant effect was seen on threshold ROP, NEC, or BPD. The decreasing trends of these outcomes in the treatment group need to be assessed and confirmed on larger sample-sizes. ..
  4. Manzoni P. Clinical Benefits of Lactoferrin for Infants and Children. J Pediatr. 2016;173 Suppl:S43-52 pubmed publisher
    ..These randomized controlled trials demonstrate that lactoferrin has a clinically significant impact on feeding, the microbiome, and clinical outcomes in neonates and infants. ..
  5. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo M, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012;129:116-23 pubmed publisher
    ..No effect is seen on colonization. The protective effect on IFI is likely due to limitation of ability of fungal colonies to progress toward invasion and systemic disease in colonized infants. ..
  6. Manzoni P, De Luca D, Stronati M, Jacqz Aigrain E, Ruffinazzi G, Luparia M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81-8 pubmed publisher
    ..Additional measures may include the use of lactoferrin, fluconazole, and nystatin and specific measures to prevent ventilator associated pneumonia. ..
  7. Manzoni P, García Sánchez R, Meyer M, Stolfi I, Pugni L, Messner H, et al. Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactoferrin Counteracts This Effect. J Pediatr. 2018;193:62-67.e1 pubmed publisher
    ..Exposure to inhibitors of gastric acidity is significantly associated with the occurrence of LOS in preterm VLBW infants. Concomitant administration of BLF counteracts this selective disadvantage. isrctn.org: ISRCTN53107700. ..